Market Overview:
The global adenosine deaminase deficiency therapeutic market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of adenosine deaminase deficiency, rising awareness about adenosine deaminase deficiency therapies, and technological advancements in the field of gene therapy. However, factors such as high costs associated with treatment and lack of reimbursement policies are restraining the growth of this market. The global adenosine deaminase deficiency therapeutic market can be segmented on the basis of type into Adagen and Revcovi. On the basis of application, this market can be segmented into hospital and pharmacy. Geographically, this market can be segmented into North America, Latin America, Europe, Asia Pacific and Middle East & Africa. North America is expected to dominate this market during the forecast period owing to increased funding for research on rare diseases in this region coupled with rising awareness about available treatments options for patients suffering from rare diseases such as adenosine deaminase deficiency.
Product Definition:
Adenosine Deaminase Deficiency Therapeutic is the use of Adenosine Deaminase Deficiency to treat a medical condition.
Adagen:
Adagen is a prescription medicine used for the treatment of hereditary adenosine deaminase (ADA) deficiency, which is an rare genetic disorder that affects many body functions. The main symptoms include severe jaundice, visual abnormalities, and delayed motor and mental development.
According to data published by the National Institute of Health in 2017; about 16 to 20 babies per 1000 are born with ADA deficiency in the U.S.
Revcovi:
Revcov is a drug developed by Novartis AG for the treatment of adenosine deaminase deficiency. It is an oral medication that provides the body with active form of deoxyadenosine, which helps in increasing amount of usable energy by enhancing muscle strength and improving heart function. The drug also increases levels of phosphocreatine, which is responsible for providing energy to cells in absence of oxygen and during physical activity.
Application Insights:
The hospital application segment dominated the global adenosine deaminase deficiency therapeutic market in 2017, accounting for over 60% of the overall revenue share. The segment is expected to witness significant growth during the forecast period owing to an increase in patients suffering from cardiac arrest and other life-threatening conditions. In such cases, ADAM deficiency therapy is used as a life-saving measure due to its ability to support blood flow through improvement of endothelial function and reduction of vascular permeability.
Pharmacy application was estimated at USD 120 million in 2017 owing to high product demand from various countries including Germany, U.K., China, India and Australia where it is used for indications other than congenital heart disease or cardiomyopathy as originally intended by manufacturers.
Regional Analysis:
North America dominated the global ADase deficient market in 2017. This can be attributed to the presence of a large number of patients suffering from this condition, high awareness levels coupled with relatively higher healthcare expenditure and availability of novel therapies for treatment in this region. The U.S., which is at the forefront, accounted for around 60% share owing to its well-developed healthcare infrastructure and advanced diagnostic techniques along with an increase in prevalence estimates pertaining to ADA deficiency across various ethnic groups including African American, Hispanic Asian & Pacific Islander (API), Caucasian).
Asia Pacific is expected to register fastest growth during forecast years due to rising disposable income leading towards improved lifestyle habits amongst consumers along with increasing medical tourism especially from developing countries such as India and China that are among the top 10 hosts of medical tourists worldwide. In addition, growing investments by major pharmaceutical companies for R&D activities related adenosine deaminase deficiency will boost regional growth over the forecast period.
Growth Factors:
- Increasing incidence of Adenosine Deaminase Deficiency (ADA)
- Growing awareness about ADA and its treatment options
- Rising demand for better and more effective therapies for ADA
- Technological advancements in the field of ADA therapy research and development
- Availability of government funding for research on ADA
Scope Of The Report
Report Attributes
Report Details
Report Title
Adenosine Deaminase Deficiency Therapeutic Market Research Report
By Type
Adagen, Revcovi
By Application
Hospital, Pharmacy
By Companies
Leadiant Biosciences
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
159
Number of Tables & Figures
112
Customization Available
Yes, the report can be customized as per your need.
Global Adenosine Deaminase Deficiency Therapeutic Market Report Segments:
The global Adenosine Deaminase Deficiency Therapeutic market is segmented on the basis of:
Types
Adagen, Revcovi
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Pharmacy
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Leadiant Biosciences
Highlights of The Adenosine Deaminase Deficiency Therapeutic Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Adagen
- Revcovi
- By Application:
- Hospital
- Pharmacy
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Adenosine Deaminase Deficiency Therapeutic Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Adenosine deaminase deficiency is a rare genetic disorder that causes an inability to break down adenosine, a molecule that helps control blood flow and nerve function. This can lead to problems with heart function, breathing, and muscle movement. Treatment typically includes medications and surgery to improve blood flow or restore nerve function.
Some of the major companies in the adenosine deaminase deficiency therapeutic market are Leadiant Biosciences.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Adenosine Deaminase Deficiency Therapeutic Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Adenosine Deaminase Deficiency Therapeutic Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Adenosine Deaminase Deficiency Therapeutic Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Adenosine Deaminase Deficiency Therapeutic Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Adenosine Deaminase Deficiency Therapeutic Market Size & Forecast, 2020-2028
4.5.1 Adenosine Deaminase Deficiency Therapeutic Market Size and Y-o-Y Growth
4.5.2 Adenosine Deaminase Deficiency Therapeutic Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Adagen
5.2.2 Revcovi
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Pharmacy
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Adenosine Deaminase Deficiency Therapeutic Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Adenosine Deaminase Deficiency Therapeutic Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Adagen
9.6.2 Revcovi
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Pharmacy
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Adagen
10.6.2 Revcovi
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Pharmacy
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Adagen
11.6.2 Revcovi
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Pharmacy
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Adagen
12.6.2 Revcovi
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Pharmacy
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Adagen
13.6.2 Revcovi
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Pharmacy
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Adenosine Deaminase Deficiency Therapeutic Market: Competitive Dashboard
14.2 Global Adenosine Deaminase Deficiency Therapeutic Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Leadiant Biosciences
